Merck Gains FDA Approval for KEYTRUDA with WELIREG in Kidney Cancer

On June 12, 2026, the U.S. FDA approved Merck & Co., Inc.'s (NYSE:MRK) KEYTRUDA (pembrolizumab) and the easier-to-administer KEYTRUDA QLEX, each in combination with WELIREG (belzutifan), for the treatment of advanced renal cell carcinoma (RCC). This decision strengthens Merck's oncology franchise.

The Product

The combination pairs KEYTRUDA, an immune checkpoint inhibitor, with WELIREG, an oral HIF-2α inhibitor. It is approved for patients with metastatic or locally advanced RCC. KEYTRUDA QLEX features a subcutaneous formulation that reduces infusion time from 30 minutes to 3-5 minutes, improving patient convenience.

Pricing and Availability

Merck has not announced official pricing yet. It is expected to be competitive with existing RCC therapies. The drug will be available immediately in the U.S. following approval.

Competition

KEYTRUDA competes with other immunotherapies like Opdivo (BMS) and Tecentriq (Roche). However, the addition of WELIREG, targeting the HIF-2α pathway, offers a unique mechanism that may improve outcomes.

Potential Impact on the Company

The approval is expected to boost KEYTRUDA sales, already one of the world's top-selling drugs. KEYTRUDA QLEX could expand the patient population. MRK stock, which makes up 2.91% of Kevin O'Leary's ETF, may attract investor interest.